Previously established biomarkers for predicting clinical outcomes of immunotherapy in NSCLC, such as PD-L1 expression, tumor mutational burden (TMB) or single genomic alterations in STK11, KEAP1, or PTEN genes, cannot accurately predict clinical benefit in all patients [89]. The gene discussed is CD274; the disease is neoplasm.